This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam Presents New Pre-clinical Data On RNAi Therapeutics For The Treatment Of Hemoglobinopathies At 54th American Society Of Hematology (ASH) Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies at the 54 th American Society of Hematology Annual Meeting being held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of β-thalassemia. These studies were conducted in collaboration with Boston Children’s Hospital. Alnylam’s program in hemoglobinopathies comprises part of its ‘Alnylam 5x15™’ product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015.

“Our ‘Alnylam 5x15’ strategy is aimed at bringing innovative medicines to patients, with a focus on RNAi therapeutics toward genetically defined targets for diseases with very high unmet medical need. ALN-TMP exemplifies this strategy where we are advancing RNAi therapeutics for the treatment of hemoglobinopathies,” said Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam. “We are very excited by these new data with ALN-TMP where we have demonstrated disease modifying effects in models of β-thalassemia, including amelioration of anemia, iron overload, extra-medullary hematopoiesis, and ineffective erythropoiesis, in addition to correction of globin gene expression.”

“Mouse genetic studies have shown that knockdown of Tmprss6 and up-regulation of the hepcidin pathway can result in disease modifying effects in models of β-thalassemia, a disease of enormous worldwide burden with limited treatment options for certain groups of patients. Our studies with ALN-TMP, an RNAi therapeutic targeting Tmprss6, recapitulate these genetic findings with an innovative pharmacologic strategy. This work is an example of how rare disease research that brings in RNA silencing technologies to ‘target the untargetable’ could rapidly lead to therapies for more common disorders,” said Mark Fleming, M.D., D.Phil., Pathologist-in-Chief at Boston Children’s Hospital and S. Burt Wolbach Professor of Pathology at Harvard Medical School, who collaborated on the work. “Specifically, we have demonstrated that ALN-TMP administration results in disease modifying effects in a model of β-thalassemia. Indeed, our studies show that ALN-TMP administration results in reduced iron overload, decreased extra-medullary hematopoiesis, increased hemoglobin levels, and a reduction in ineffective erythropoiesis. Further, we have found that these effects are accompanied by a decrease in membrane-associated hemoglobin, one of the primary causes of the decreased red blood cell survival in β-thalassemia. Clearly, these results could be of significance for the treatment of patients with β-thalassemia and possibly other hemoglobinopathies.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs